NEW YORK, May 6, 2014 – Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) ...

MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...

MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...

NEW YORK, May 5, 2014 – Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance ...

MALVERN, Pa., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. STIM, a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality ...

MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the ...

NeuroStar TMS Therapy, a non-pharmacologic treatment, demonstrated positive results for women with postpartum depression. NeuroStar TMS Therapy, a non-pharmacologic treatment, demonstrated positive ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. Neuronetics announced that Evernorth will offer coverage for its NeuroStar Transcranial Magnetic ...

MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...

MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...